nodes	percent_of_prediction	percent_of_DWPC	metapath
Dofetilide—Rosiglitazone—type 2 diabetes mellitus	0.482	1	CrCtD
Dofetilide—Rosiglitazone—Pioglitazone—type 2 diabetes mellitus	0.271	1	CrCrCtD
Dofetilide—CYP3A4—type 2 diabetes mellitus	0.0812	1	CbGaD
Dofetilide—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0129	0.152	CbGbCtD
Dofetilide—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0115	0.136	CbGbCtD
Dofetilide—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0105	0.124	CbGbCtD
Dofetilide—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00917	0.109	CbGbCtD
Dofetilide—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00829	0.0982	CbGbCtD
Dofetilide—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00628	0.0744	CbGbCtD
Dofetilide—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00602	0.0713	CbGbCtD
Dofetilide—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00602	0.0713	CbGbCtD
Dofetilide—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0057	0.0675	CbGbCtD
Dofetilide—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00424	0.0503	CbGbCtD
Dofetilide—CYP3A4—Losartan—type 2 diabetes mellitus	0.00388	0.046	CbGbCtD
Dofetilide—KCNK2—Tandem pore domain potassium channels—KCNK16—type 2 diabetes mellitus	0.00378	0.145	CbGpPWpGaD
Dofetilide—KCNJ12—Inwardly rectifying K+ channels—ABCC8—type 2 diabetes mellitus	0.00146	0.0561	CbGpPWpGaD
Dofetilide—KCNJ12—Inwardly rectifying K+ channels—KCNJ11—type 2 diabetes mellitus	0.00116	0.0443	CbGpPWpGaD
Dofetilide—KCNJ12—Potassium Channels—KCNK16—type 2 diabetes mellitus	0.0011	0.0422	CbGpPWpGaD
Dofetilide—KCNJ12—Potassium Channels—KCNQ1—type 2 diabetes mellitus	0.000762	0.0292	CbGpPWpGaD
Dofetilide—KCNJ12—Activation of G protein gated Potassium channels—GNB3—type 2 diabetes mellitus	0.000731	0.028	CbGpPWpGaD
Dofetilide—KCNK2—Potassium Channels—KCNK16—type 2 diabetes mellitus	0.000698	0.0268	CbGpPWpGaD
Dofetilide—KCNJ12—Inwardly rectifying K+ channels—GNB3—type 2 diabetes mellitus	0.000616	0.0236	CbGpPWpGaD
Dofetilide—KCNJ12—Potassium Channels—ABCC8—type 2 diabetes mellitus	0.000578	0.0222	CbGpPWpGaD
Dofetilide—KCNJ12—Activation of GABAB receptors—GNB3—type 2 diabetes mellitus	0.000523	0.0201	CbGpPWpGaD
Dofetilide—KCNK2—Potassium Channels—KCNQ1—type 2 diabetes mellitus	0.000484	0.0186	CbGpPWpGaD
Dofetilide—KCNJ12—Neuronal System—KCNK16—type 2 diabetes mellitus	0.00048	0.0184	CbGpPWpGaD
Dofetilide—KCNJ12—Activation of GABAB receptors—ADCY5—type 2 diabetes mellitus	0.000466	0.0179	CbGpPWpGaD
Dofetilide—KCNJ12—Potassium Channels—KCNJ11—type 2 diabetes mellitus	0.000457	0.0175	CbGpPWpGaD
Dofetilide—KCNJ12—GABA receptor activation—GNB3—type 2 diabetes mellitus	0.000401	0.0154	CbGpPWpGaD
Dofetilide—KCNH2—Voltage gated Potassium channels—KCNQ1—type 2 diabetes mellitus	0.000399	0.0153	CbGpPWpGaD
Dofetilide—CYP3A4—Felbamate Metabolism—CYP2E1—type 2 diabetes mellitus	0.000381	0.0146	CbGpPWpGaD
Dofetilide—CYP3A4—Lidocaine metabolism—CYP1A2—type 2 diabetes mellitus	0.000377	0.0145	CbGpPWpGaD
Dofetilide—KCNK2—Potassium Channels—ABCC8—type 2 diabetes mellitus	0.000367	0.0141	CbGpPWpGaD
Dofetilide—KCNJ12—GABA receptor activation—ADCY5—type 2 diabetes mellitus	0.000357	0.0137	CbGpPWpGaD
Dofetilide—Rosiglitazone—PPARG—type 2 diabetes mellitus	0.000334	0.282	CrCbGaD
Dofetilide—KCNJ12—Neuronal System—KCNQ1—type 2 diabetes mellitus	0.000333	0.0128	CbGpPWpGaD
Dofetilide—KCNK2—Neuronal System—KCNK16—type 2 diabetes mellitus	0.000305	0.0117	CbGpPWpGaD
Dofetilide—KCNH2—Potassium Channels—KCNK16—type 2 diabetes mellitus	0.000296	0.0113	CbGpPWpGaD
Dofetilide—KCNK2—Potassium Channels—KCNJ11—type 2 diabetes mellitus	0.00029	0.0111	CbGpPWpGaD
Dofetilide—KCNJ12—Transmission across Chemical Synapses—GAD2—type 2 diabetes mellitus	0.000288	0.011	CbGpPWpGaD
Dofetilide—Dronedarone—ADRA2A—type 2 diabetes mellitus	0.000273	0.23	CrCbGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—PHOX2A—type 2 diabetes mellitus	0.000271	0.0104	CbGpPWpGaD
Dofetilide—KCNJ12—Neuronal System—ABCC8—type 2 diabetes mellitus	0.000252	0.00967	CbGpPWpGaD
Dofetilide—KCNJ12—Potassium Channels—GNB3—type 2 diabetes mellitus	0.000243	0.00933	CbGpPWpGaD
Dofetilide—KCNJ12—Neuronal System—GAD2—type 2 diabetes mellitus	0.00022	0.00846	CbGpPWpGaD
Dofetilide—Rosiglitazone—CYP1A2—type 2 diabetes mellitus	0.000218	0.184	CrCbGaD
Dofetilide—KCNK2—Neuronal System—KCNQ1—type 2 diabetes mellitus	0.000211	0.00811	CbGpPWpGaD
Dofetilide—KCNH2—Potassium Channels—KCNQ1—type 2 diabetes mellitus	0.000205	0.00786	CbGpPWpGaD
Dofetilide—KCNJ12—Neuronal System—KCNJ11—type 2 diabetes mellitus	0.000199	0.00765	CbGpPWpGaD
Dofetilide—KCNJ12—Transmission across Chemical Synapses—SNAP25—type 2 diabetes mellitus	0.000185	0.00711	CbGpPWpGaD
Dofetilide—CYP3A4—Codeine and Morphine Metabolism—ABCC2—type 2 diabetes mellitus	0.000185	0.0071	CbGpPWpGaD
Dofetilide—KCNJ12—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNB3—type 2 diabetes mellitus	0.000184	0.00707	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—NEUROD1—type 2 diabetes mellitus	0.000175	0.0067	CbGpPWpGaD
Dofetilide—KCNJ12—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—type 2 diabetes mellitus	0.000164	0.0063	CbGpPWpGaD
Dofetilide—KCNK2—Neuronal System—ABCC8—type 2 diabetes mellitus	0.00016	0.00614	CbGpPWpGaD
Dofetilide—KCNH2—Potassium Channels—ABCC8—type 2 diabetes mellitus	0.000155	0.00596	CbGpPWpGaD
Dofetilide—KCNK2—Potassium Channels—GNB3—type 2 diabetes mellitus	0.000154	0.00592	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—KCNQ1—type 2 diabetes mellitus	0.000142	0.00546	CbGpPWpGaD
Dofetilide—KCNJ12—Neuronal System—SNAP25—type 2 diabetes mellitus	0.000142	0.00545	CbGpPWpGaD
Dofetilide—KCNJ12—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CALM1—type 2 diabetes mellitus	0.000141	0.00541	CbGpPWpGaD
Dofetilide—KCNK2—Neuronal System—GAD2—type 2 diabetes mellitus	0.00014	0.00537	CbGpPWpGaD
Dofetilide—KCNJ12—Transmission across Chemical Synapses—GNB3—type 2 diabetes mellitus	0.000139	0.00531	CbGpPWpGaD
Dofetilide—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—type 2 diabetes mellitus	0.000138	0.00531	CbGpPWpGaD
Dofetilide—KCNJ12—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCB—type 2 diabetes mellitus	0.000133	0.00509	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—ECE1—type 2 diabetes mellitus	0.000132	0.00508	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—G6PC—type 2 diabetes mellitus	0.000132	0.00508	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—KCNK16—type 2 diabetes mellitus	0.000129	0.00495	CbGpPWpGaD
Dofetilide—KCNK2—Neuronal System—KCNJ11—type 2 diabetes mellitus	0.000127	0.00486	CbGpPWpGaD
Dofetilide—Rosiglitazone—ALB—type 2 diabetes mellitus	0.000126	0.106	CrCbGaD
Dofetilide—Dronedarone—CYP3A4—type 2 diabetes mellitus	0.000125	0.106	CrCbGaD
Dofetilide—KCNJ12—Transmission across Chemical Synapses—ADCY5—type 2 diabetes mellitus	0.000123	0.00474	CbGpPWpGaD
Dofetilide—KCNH2—Potassium Channels—KCNJ11—type 2 diabetes mellitus	0.000123	0.00471	CbGpPWpGaD
Dofetilide—CYP3A4—Irinotecan Pathway—ABCC2—type 2 diabetes mellitus	0.000118	0.00454	CbGpPWpGaD
Dofetilide—CYP3A4—Liver X Receptor Pathway—SREBF1—type 2 diabetes mellitus	0.000115	0.00441	CbGpPWpGaD
Dofetilide—Dronedarone—ALB—type 2 diabetes mellitus	0.000109	0.0923	CrCbGaD
Dofetilide—KCNJ12—Neuronal System—GNB3—type 2 diabetes mellitus	0.000106	0.00407	CbGpPWpGaD
Dofetilide—KCNJ12—Transmission across Chemical Synapses—CALM1—type 2 diabetes mellitus	0.000106	0.00407	CbGpPWpGaD
Dofetilide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—type 2 diabetes mellitus	0.000106	0.00407	CbGpPWpGaD
Dofetilide—Shock—Bromocriptine—type 2 diabetes mellitus	0.000103	0.00192	CcSEcCtD
Dofetilide—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000103	0.00192	CcSEcCtD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYB5R4—type 2 diabetes mellitus	0.000103	0.00394	CbGpPWpGaD
Dofetilide—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000102	0.0019	CcSEcCtD
Dofetilide—Back pain—Gliclazide—type 2 diabetes mellitus	0.000102	0.0019	CcSEcCtD
Dofetilide—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	0.000102	0.00189	CcSEcCtD
Dofetilide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—type 2 diabetes mellitus	0.000101	0.00388	CbGpPWpGaD
Dofetilide—Arthralgia—Glyburide—type 2 diabetes mellitus	9.98e-05	0.00186	CcSEcCtD
Dofetilide—KCNJ12—Transmission across Chemical Synapses—PRKCB—type 2 diabetes mellitus	9.97e-05	0.00382	CbGpPWpGaD
Dofetilide—Oedema peripheral—Metformin—type 2 diabetes mellitus	9.97e-05	0.00186	CcSEcCtD
Dofetilide—Pain—Sitagliptin—type 2 diabetes mellitus	9.89e-05	0.00184	CcSEcCtD
Dofetilide—Abdominal pain—Glipizide—type 2 diabetes mellitus	9.83e-05	0.00183	CcSEcCtD
Dofetilide—Urinary tract infection—Losartan—type 2 diabetes mellitus	9.73e-05	0.00181	CcSEcCtD
Dofetilide—Bradycardia—Irbesartan—type 2 diabetes mellitus	9.72e-05	0.00181	CcSEcCtD
Dofetilide—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	9.72e-05	0.00181	CcSEcCtD
Dofetilide—Influenza—Ramipril—type 2 diabetes mellitus	9.62e-05	0.00179	CcSEcCtD
Dofetilide—Angioedema—Gliclazide—type 2 diabetes mellitus	9.62e-05	0.00179	CcSEcCtD
Dofetilide—Sweating—Losartan—type 2 diabetes mellitus	9.59e-05	0.00179	CcSEcCtD
Dofetilide—Oedema—Glyburide—type 2 diabetes mellitus	9.57e-05	0.00178	CcSEcCtD
Dofetilide—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	9.49e-05	0.00177	CcSEcCtD
Dofetilide—Rash—Repaglinide—type 2 diabetes mellitus	9.47e-05	0.00177	CcSEcCtD
Dofetilide—Insomnia—Bromocriptine—type 2 diabetes mellitus	9.47e-05	0.00176	CcSEcCtD
Dofetilide—Dermatitis—Repaglinide—type 2 diabetes mellitus	9.46e-05	0.00176	CcSEcCtD
Dofetilide—KCNJ12—Neuronal System—ADCY5—type 2 diabetes mellitus	9.46e-05	0.00363	CbGpPWpGaD
Dofetilide—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	9.46e-05	0.00176	CcSEcCtD
Dofetilide—Headache—Repaglinide—type 2 diabetes mellitus	9.41e-05	0.00175	CcSEcCtD
Dofetilide—Shock—Glyburide—type 2 diabetes mellitus	9.41e-05	0.00175	CcSEcCtD
Dofetilide—Oedema peripheral—Irbesartan—type 2 diabetes mellitus	9.4e-05	0.00175	CcSEcCtD
Dofetilide—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	9.4e-05	0.00175	CcSEcCtD
Dofetilide—Dizziness—Rosiglitazone—type 2 diabetes mellitus	9.39e-05	0.00175	CcSEcCtD
Dofetilide—Angina pectoris—Ramipril—type 2 diabetes mellitus	9.38e-05	0.00175	CcSEcCtD
Dofetilide—Back pain—Valsartan—type 2 diabetes mellitus	9.35e-05	0.00174	CcSEcCtD
Dofetilide—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	9.33e-05	0.00174	CcSEcCtD
Dofetilide—Palpitations—Gliclazide—type 2 diabetes mellitus	9.3e-05	0.00173	CcSEcCtD
Dofetilide—Loss of consciousness—Gliclazide—type 2 diabetes mellitus	9.25e-05	0.00172	CcSEcCtD
Dofetilide—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	9.25e-05	0.00172	CcSEcCtD
Dofetilide—Back pain—Orlistat—type 2 diabetes mellitus	9.24e-05	0.00172	CcSEcCtD
Dofetilide—Cough—Gliclazide—type 2 diabetes mellitus	9.18e-05	0.00171	CcSEcCtD
Dofetilide—Abdominal pain—Glimepiride—type 2 diabetes mellitus	9.17e-05	0.00171	CcSEcCtD
Dofetilide—CYP3A4—Tryptophan metabolism—AANAT—type 2 diabetes mellitus	9.17e-05	0.00352	CbGpPWpGaD
Dofetilide—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	9.14e-05	0.0017	CcSEcCtD
Dofetilide—Hypertension—Gliclazide—type 2 diabetes mellitus	9.09e-05	0.00169	CcSEcCtD
Dofetilide—KCNK2—Neuronal System—SNAP25—type 2 diabetes mellitus	9.02e-05	0.00346	CbGpPWpGaD
Dofetilide—Arthralgia—Gliclazide—type 2 diabetes mellitus	8.96e-05	0.00167	CcSEcCtD
Dofetilide—Chest pain—Gliclazide—type 2 diabetes mellitus	8.96e-05	0.00167	CcSEcCtD
Dofetilide—Rash—Rosiglitazone—type 2 diabetes mellitus	8.95e-05	0.00167	CcSEcCtD
Dofetilide—KCNH2—Neuronal System—KCNQ1—type 2 diabetes mellitus	8.95e-05	0.00343	CbGpPWpGaD
Dofetilide—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	8.95e-05	0.00167	CcSEcCtD
Dofetilide—Anxiety—Gliclazide—type 2 diabetes mellitus	8.93e-05	0.00166	CcSEcCtD
Dofetilide—Nausea—Repaglinide—type 2 diabetes mellitus	8.92e-05	0.00166	CcSEcCtD
Dofetilide—Asthenia—Glipizide—type 2 diabetes mellitus	8.92e-05	0.00166	CcSEcCtD
Dofetilide—Headache—Rosiglitazone—type 2 diabetes mellitus	8.9e-05	0.00166	CcSEcCtD
Dofetilide—Angioedema—Valsartan—type 2 diabetes mellitus	8.84e-05	0.00165	CcSEcCtD
Dofetilide—Angioedema—Orlistat—type 2 diabetes mellitus	8.73e-05	0.00163	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	8.72e-05	0.00162	CcSEcCtD
Dofetilide—Syncope—Valsartan—type 2 diabetes mellitus	8.67e-05	0.00162	CcSEcCtD
Dofetilide—Paraesthesia—Glyburide—type 2 diabetes mellitus	8.59e-05	0.0016	CcSEcCtD
Dofetilide—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	8.56e-05	0.00159	CcSEcCtD
Dofetilide—Palpitations—Valsartan—type 2 diabetes mellitus	8.55e-05	0.00159	CcSEcCtD
Dofetilide—Asthenia—Pioglitazone—type 2 diabetes mellitus	8.54e-05	0.00159	CcSEcCtD
Dofetilide—Dyspnoea—Glyburide—type 2 diabetes mellitus	8.53e-05	0.00159	CcSEcCtD
Dofetilide—Arrhythmia—Irbesartan—type 2 diabetes mellitus	8.53e-05	0.00159	CcSEcCtD
Dofetilide—Diarrhoea—Glipizide—type 2 diabetes mellitus	8.51e-05	0.00159	CcSEcCtD
Dofetilide—Loss of consciousness—Valsartan—type 2 diabetes mellitus	8.5e-05	0.00158	CcSEcCtD
Dofetilide—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	8.46e-05	0.00158	CcSEcCtD
Dofetilide—Palpitations—Orlistat—type 2 diabetes mellitus	8.44e-05	0.00157	CcSEcCtD
Dofetilide—Cough—Valsartan—type 2 diabetes mellitus	8.44e-05	0.00157	CcSEcCtD
Dofetilide—Nausea—Rosiglitazone—type 2 diabetes mellitus	8.43e-05	0.00157	CcSEcCtD
Dofetilide—Myocardial infarction—Ramipril—type 2 diabetes mellitus	8.41e-05	0.00157	CcSEcCtD
Dofetilide—Urinary tract infection—Ramipril—type 2 diabetes mellitus	8.34e-05	0.00155	CcSEcCtD
Dofetilide—Cough—Orlistat—type 2 diabetes mellitus	8.34e-05	0.00155	CcSEcCtD
Dofetilide—Asthenia—Glimepiride—type 2 diabetes mellitus	8.32e-05	0.00155	CcSEcCtD
Dofetilide—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	8.3e-05	0.00155	CcSEcCtD
Dofetilide—Asthenia—Sitagliptin—type 2 diabetes mellitus	8.3e-05	0.00155	CcSEcCtD
Dofetilide—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	8.27e-05	0.00154	CcSEcCtD
Dofetilide—Chest pain—Valsartan—type 2 diabetes mellitus	8.23e-05	0.00153	CcSEcCtD
Dofetilide—Arthralgia—Valsartan—type 2 diabetes mellitus	8.23e-05	0.00153	CcSEcCtD
Dofetilide—Sweating—Ramipril—type 2 diabetes mellitus	8.23e-05	0.00153	CcSEcCtD
Dofetilide—Dizziness—Glipizide—type 2 diabetes mellitus	8.22e-05	0.00153	CcSEcCtD
Dofetilide—Anxiety—Valsartan—type 2 diabetes mellitus	8.2e-05	0.00153	CcSEcCtD
Dofetilide—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	8.15e-05	0.00152	CcSEcCtD
Dofetilide—Chest pain—Orlistat—type 2 diabetes mellitus	8.14e-05	0.00152	CcSEcCtD
Dofetilide—KCNJ12—Neuronal System—CALM1—type 2 diabetes mellitus	8.13e-05	0.00312	CbGpPWpGaD
Dofetilide—Anxiety—Orlistat—type 2 diabetes mellitus	8.11e-05	0.00151	CcSEcCtD
Dofetilide—Arrhythmia—Losartan—type 2 diabetes mellitus	8.03e-05	0.0015	CcSEcCtD
Dofetilide—Diarrhoea—Glimepiride—type 2 diabetes mellitus	7.94e-05	0.00148	CcSEcCtD
Dofetilide—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	7.91e-05	0.00147	CcSEcCtD
Dofetilide—Syncope—Metformin—type 2 diabetes mellitus	7.9e-05	0.00147	CcSEcCtD
Dofetilide—Oedema—Valsartan—type 2 diabetes mellitus	7.89e-05	0.00147	CcSEcCtD
Dofetilide—Dizziness—Pioglitazone—type 2 diabetes mellitus	7.87e-05	0.00147	CcSEcCtD
Dofetilide—Rash—Glipizide—type 2 diabetes mellitus	7.84e-05	0.00146	CcSEcCtD
Dofetilide—Dermatitis—Glipizide—type 2 diabetes mellitus	7.83e-05	0.00146	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	7.83e-05	0.00146	CcSEcCtD
Dofetilide—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	7.82e-05	0.00146	CcSEcCtD
Dofetilide—Oedema—Orlistat—type 2 diabetes mellitus	7.8e-05	0.00145	CcSEcCtD
Dofetilide—Headache—Glipizide—type 2 diabetes mellitus	7.79e-05	0.00145	CcSEcCtD
Dofetilide—Palpitations—Metformin—type 2 diabetes mellitus	7.78e-05	0.00145	CcSEcCtD
Dofetilide—Insomnia—Gliclazide—type 2 diabetes mellitus	7.77e-05	0.00145	CcSEcCtD
Dofetilide—Shock—Valsartan—type 2 diabetes mellitus	7.76e-05	0.00145	CcSEcCtD
Dofetilide—Loss of consciousness—Metformin—type 2 diabetes mellitus	7.74e-05	0.00144	CcSEcCtD
Dofetilide—Paraesthesia—Gliclazide—type 2 diabetes mellitus	7.71e-05	0.00144	CcSEcCtD
Dofetilide—Dizziness—Glimepiride—type 2 diabetes mellitus	7.67e-05	0.00143	CcSEcCtD
Dofetilide—Dyspnoea—Gliclazide—type 2 diabetes mellitus	7.66e-05	0.00143	CcSEcCtD
Dofetilide—Dizziness—Sitagliptin—type 2 diabetes mellitus	7.65e-05	0.00143	CcSEcCtD
Dofetilide—KCNJ12—Neuronal System—PRKCB—type 2 diabetes mellitus	7.64e-05	0.00293	CbGpPWpGaD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA6—type 2 diabetes mellitus	7.62e-05	0.00292	CbGpPWpGaD
Dofetilide—Hypertension—Metformin—type 2 diabetes mellitus	7.6e-05	0.00142	CcSEcCtD
Dofetilide—Angioedema—Irbesartan—type 2 diabetes mellitus	7.59e-05	0.00142	CcSEcCtD
Dofetilide—Oedema peripheral—Ramipril—type 2 diabetes mellitus	7.59e-05	0.00141	CcSEcCtD
Dofetilide—Back pain—Losartan—type 2 diabetes mellitus	7.57e-05	0.00141	CcSEcCtD
Dofetilide—Abdominal pain—Glyburide—type 2 diabetes mellitus	7.56e-05	0.00141	CcSEcCtD
Dofetilide—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	7.54e-05	0.00141	CcSEcCtD
Dofetilide—Asthenia—Bromocriptine—type 2 diabetes mellitus	7.51e-05	0.0014	CcSEcCtD
Dofetilide—Chest pain—Metformin—type 2 diabetes mellitus	7.5e-05	0.0014	CcSEcCtD
Dofetilide—Headache—Pioglitazone—type 2 diabetes mellitus	7.46e-05	0.00139	CcSEcCtD
Dofetilide—Syncope—Irbesartan—type 2 diabetes mellitus	7.45e-05	0.00139	CcSEcCtD
Dofetilide—Nausea—Glipizide—type 2 diabetes mellitus	7.38e-05	0.00138	CcSEcCtD
Dofetilide—Pain—Gliclazide—type 2 diabetes mellitus	7.35e-05	0.00137	CcSEcCtD
Dofetilide—Rash—Glimepiride—type 2 diabetes mellitus	7.31e-05	0.00136	CcSEcCtD
Dofetilide—Dermatitis—Glimepiride—type 2 diabetes mellitus	7.31e-05	0.00136	CcSEcCtD
Dofetilide—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	7.3e-05	0.00136	CcSEcCtD
Dofetilide—Rash—Sitagliptin—type 2 diabetes mellitus	7.29e-05	0.00136	CcSEcCtD
Dofetilide—Dermatitis—Sitagliptin—type 2 diabetes mellitus	7.28e-05	0.00136	CcSEcCtD
Dofetilide—Headache—Glimepiride—type 2 diabetes mellitus	7.27e-05	0.00135	CcSEcCtD
Dofetilide—Cough—Irbesartan—type 2 diabetes mellitus	7.25e-05	0.00135	CcSEcCtD
Dofetilide—Headache—Sitagliptin—type 2 diabetes mellitus	7.24e-05	0.00135	CcSEcCtD
Dofetilide—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—type 2 diabetes mellitus	7.22e-05	0.00277	CbGpPWpGaD
Dofetilide—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	7.19e-05	0.00134	CcSEcCtD
Dofetilide—Oedema—Metformin—type 2 diabetes mellitus	7.19e-05	0.00134	CcSEcCtD
Dofetilide—Hypertension—Irbesartan—type 2 diabetes mellitus	7.18e-05	0.00134	CcSEcCtD
Dofetilide—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	7.16e-05	0.00133	CcSEcCtD
Dofetilide—Angioedema—Losartan—type 2 diabetes mellitus	7.15e-05	0.00133	CcSEcCtD
Dofetilide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—type 2 diabetes mellitus	7.14e-05	0.00274	CbGpPWpGaD
Dofetilide—Insomnia—Valsartan—type 2 diabetes mellitus	7.14e-05	0.00133	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	7.11e-05	0.00132	CcSEcCtD
Dofetilide—Paraesthesia—Valsartan—type 2 diabetes mellitus	7.09e-05	0.00132	CcSEcCtD
Dofetilide—Arthralgia—Irbesartan—type 2 diabetes mellitus	7.08e-05	0.00132	CcSEcCtD
Dofetilide—Chest pain—Irbesartan—type 2 diabetes mellitus	7.08e-05	0.00132	CcSEcCtD
Dofetilide—Shock—Metformin—type 2 diabetes mellitus	7.07e-05	0.00132	CcSEcCtD
Dofetilide—Insomnia—Orlistat—type 2 diabetes mellitus	7.05e-05	0.00131	CcSEcCtD
Dofetilide—Anxiety—Irbesartan—type 2 diabetes mellitus	7.05e-05	0.00131	CcSEcCtD
Dofetilide—Dyspnoea—Valsartan—type 2 diabetes mellitus	7.04e-05	0.00131	CcSEcCtD
Dofetilide—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	7.02e-05	0.00131	CcSEcCtD
Dofetilide—Syncope—Losartan—type 2 diabetes mellitus	7.01e-05	0.00131	CcSEcCtD
Dofetilide—Paraesthesia—Orlistat—type 2 diabetes mellitus	7e-05	0.00131	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—CPT1A—type 2 diabetes mellitus	6.96e-05	0.00267	CbGpPWpGaD
Dofetilide—Hyperhidrosis—Metformin—type 2 diabetes mellitus	6.95e-05	0.00129	CcSEcCtD
Dofetilide—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.92e-05	0.00129	CcSEcCtD
Dofetilide—Palpitations—Losartan—type 2 diabetes mellitus	6.91e-05	0.00129	CcSEcCtD
Dofetilide—Nausea—Glimepiride—type 2 diabetes mellitus	6.89e-05	0.00128	CcSEcCtD
Dofetilide—Arrhythmia—Ramipril—type 2 diabetes mellitus	6.88e-05	0.00128	CcSEcCtD
Dofetilide—Loss of consciousness—Losartan—type 2 diabetes mellitus	6.87e-05	0.00128	CcSEcCtD
Dofetilide—Nausea—Sitagliptin—type 2 diabetes mellitus	6.87e-05	0.00128	CcSEcCtD
Dofetilide—Asthenia—Glyburide—type 2 diabetes mellitus	6.86e-05	0.00128	CcSEcCtD
Dofetilide—Cough—Losartan—type 2 diabetes mellitus	6.82e-05	0.00127	CcSEcCtD
Dofetilide—Abdominal pain—Gliclazide—type 2 diabetes mellitus	6.79e-05	0.00127	CcSEcCtD
Dofetilide—Oedema—Irbesartan—type 2 diabetes mellitus	6.78e-05	0.00126	CcSEcCtD
Dofetilide—KCNH2—Neuronal System—ABCC8—type 2 diabetes mellitus	6.78e-05	0.0026	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—GCK—type 2 diabetes mellitus	6.78e-05	0.0026	CbGpPWpGaD
Dofetilide—KCNK2—Neuronal System—GNB3—type 2 diabetes mellitus	6.74e-05	0.00259	CbGpPWpGaD
Dofetilide—Shock—Irbesartan—type 2 diabetes mellitus	6.67e-05	0.00124	CcSEcCtD
Dofetilide—Pain—Orlistat—type 2 diabetes mellitus	6.67e-05	0.00124	CcSEcCtD
Dofetilide—Arthralgia—Losartan—type 2 diabetes mellitus	6.66e-05	0.00124	CcSEcCtD
Dofetilide—Chest pain—Losartan—type 2 diabetes mellitus	6.66e-05	0.00124	CcSEcCtD
Dofetilide—Anxiety—Losartan—type 2 diabetes mellitus	6.64e-05	0.00124	CcSEcCtD
Dofetilide—Rash—Bromocriptine—type 2 diabetes mellitus	6.6e-05	0.00123	CcSEcCtD
Dofetilide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.59e-05	0.00123	CcSEcCtD
Dofetilide—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	6.56e-05	0.00122	CcSEcCtD
Dofetilide—Headache—Bromocriptine—type 2 diabetes mellitus	6.56e-05	0.00122	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.55e-05	0.00122	CcSEcCtD
Dofetilide—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.55e-05	0.00122	CcSEcCtD
Dofetilide—KCNH2—Potassium Channels—GNB3—type 2 diabetes mellitus	6.54e-05	0.00251	CbGpPWpGaD
Dofetilide—CYP3A4—Estrogen metabolism—CYP1A2—type 2 diabetes mellitus	6.5e-05	0.00249	CbGpPWpGaD
Dofetilide—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.45e-05	0.0012	CcSEcCtD
Dofetilide—Paraesthesia—Metformin—type 2 diabetes mellitus	6.45e-05	0.0012	CcSEcCtD
Dofetilide—Dyspnoea—Metformin—type 2 diabetes mellitus	6.41e-05	0.00119	CcSEcCtD
Dofetilide—Oedema—Losartan—type 2 diabetes mellitus	6.38e-05	0.00119	CcSEcCtD
Dofetilide—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.38e-05	0.00119	CcSEcCtD
Dofetilide—Shock—Losartan—type 2 diabetes mellitus	6.28e-05	0.00117	CcSEcCtD
Dofetilide—Abdominal pain—Valsartan—type 2 diabetes mellitus	6.24e-05	0.00116	CcSEcCtD
Dofetilide—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—type 2 diabetes mellitus	6.23e-05	0.00239	CbGpPWpGaD
Dofetilide—Nausea—Bromocriptine—type 2 diabetes mellitus	6.22e-05	0.00116	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.18e-05	0.00115	CcSEcCtD
Dofetilide—Hyperhidrosis—Losartan—type 2 diabetes mellitus	6.17e-05	0.00115	CcSEcCtD
Dofetilide—Abdominal pain—Orlistat—type 2 diabetes mellitus	6.17e-05	0.00115	CcSEcCtD
Dofetilide—Asthenia—Gliclazide—type 2 diabetes mellitus	6.16e-05	0.00115	CcSEcCtD
Dofetilide—Angioedema—Ramipril—type 2 diabetes mellitus	6.13e-05	0.00114	CcSEcCtD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—type 2 diabetes mellitus	6.1e-05	0.00234	CbGpPWpGaD
Dofetilide—Paraesthesia—Irbesartan—type 2 diabetes mellitus	6.09e-05	0.00114	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—SNAP25—type 2 diabetes mellitus	6.08e-05	0.00233	CbGpPWpGaD
Dofetilide—Dyspnoea—Irbesartan—type 2 diabetes mellitus	6.05e-05	0.00113	CcSEcCtD
Dofetilide—CYP3A4—Xenobiotics—CYP2E1—type 2 diabetes mellitus	6.04e-05	0.00232	CbGpPWpGaD
Dofetilide—Rash—Glyburide—type 2 diabetes mellitus	6.03e-05	0.00112	CcSEcCtD
Dofetilide—Dermatitis—Glyburide—type 2 diabetes mellitus	6.03e-05	0.00112	CcSEcCtD
Dofetilide—Syncope—Ramipril—type 2 diabetes mellitus	6.01e-05	0.00112	CcSEcCtD
Dofetilide—KCNK2—Neuronal System—ADCY5—type 2 diabetes mellitus	6.01e-05	0.0023	CbGpPWpGaD
Dofetilide—Headache—Glyburide—type 2 diabetes mellitus	5.99e-05	0.00112	CcSEcCtD
Dofetilide—CYP3A4—Xenobiotics—CYP1A2—type 2 diabetes mellitus	5.98e-05	0.00229	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—GAD2—type 2 diabetes mellitus	5.93e-05	0.00227	CbGpPWpGaD
Dofetilide—Palpitations—Ramipril—type 2 diabetes mellitus	5.93e-05	0.0011	CcSEcCtD
Dofetilide—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.89e-05	0.0011	CcSEcCtD
Dofetilide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.88e-05	0.0011	CcSEcCtD
Dofetilide—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.88e-05	0.0011	CcSEcCtD
Dofetilide—Cough—Ramipril—type 2 diabetes mellitus	5.85e-05	0.00109	CcSEcCtD
Dofetilide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—type 2 diabetes mellitus	5.82e-05	0.00223	CbGpPWpGaD
Dofetilide—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.82e-05	0.00108	CcSEcCtD
Dofetilide—CYP3A4—Tamoxifen metabolism—CYP2E1—type 2 diabetes mellitus	5.81e-05	0.00223	CbGpPWpGaD
Dofetilide—Pain—Irbesartan—type 2 diabetes mellitus	5.8e-05	0.00108	CcSEcCtD
Dofetilide—Insomnia—Losartan—type 2 diabetes mellitus	5.77e-05	0.00108	CcSEcCtD
Dofetilide—CYP3A4—Tamoxifen metabolism—CYP1A2—type 2 diabetes mellitus	5.75e-05	0.0022	CbGpPWpGaD
Dofetilide—Paraesthesia—Losartan—type 2 diabetes mellitus	5.73e-05	0.00107	CcSEcCtD
Dofetilide—Chest pain—Ramipril—type 2 diabetes mellitus	5.71e-05	0.00106	CcSEcCtD
Dofetilide—Arthralgia—Ramipril—type 2 diabetes mellitus	5.71e-05	0.00106	CcSEcCtD
Dofetilide—Dyspnoea—Losartan—type 2 diabetes mellitus	5.69e-05	0.00106	CcSEcCtD
Dofetilide—Anxiety—Ramipril—type 2 diabetes mellitus	5.69e-05	0.00106	CcSEcCtD
Dofetilide—Nausea—Glyburide—type 2 diabetes mellitus	5.68e-05	0.00106	CcSEcCtD
Dofetilide—Abdominal pain—Metformin—type 2 diabetes mellitus	5.68e-05	0.00106	CcSEcCtD
Dofetilide—Dizziness—Gliclazide—type 2 diabetes mellitus	5.68e-05	0.00106	CcSEcCtD
Dofetilide—Asthenia—Valsartan—type 2 diabetes mellitus	5.66e-05	0.00106	CcSEcCtD
Dofetilide—Asthenia—Orlistat—type 2 diabetes mellitus	5.6e-05	0.00104	CcSEcCtD
Dofetilide—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.55e-05	0.00103	CcSEcCtD
Dofetilide—Oedema—Ramipril—type 2 diabetes mellitus	5.47e-05	0.00102	CcSEcCtD
Dofetilide—Pain—Losartan—type 2 diabetes mellitus	5.46e-05	0.00102	CcSEcCtD
Dofetilide—Rash—Gliclazide—type 2 diabetes mellitus	5.42e-05	0.00101	CcSEcCtD
Dofetilide—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.41e-05	0.00101	CcSEcCtD
Dofetilide—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.4e-05	0.00101	CcSEcCtD
Dofetilide—Shock—Ramipril—type 2 diabetes mellitus	5.38e-05	0.001	CcSEcCtD
Dofetilide—Headache—Gliclazide—type 2 diabetes mellitus	5.38e-05	0.001	CcSEcCtD
Dofetilide—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.36e-05	0.000999	CcSEcCtD
Dofetilide—KCNH2—Neuronal System—KCNJ11—type 2 diabetes mellitus	5.36e-05	0.00206	CbGpPWpGaD
Dofetilide—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.34e-05	0.000994	CcSEcCtD
Dofetilide—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	5.29e-05	0.000986	CcSEcCtD
Dofetilide—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.22e-05	0.000973	CcSEcCtD
Dofetilide—Dizziness—Valsartan—type 2 diabetes mellitus	5.22e-05	0.000973	CcSEcCtD
Dofetilide—KCNK2—Neuronal System—CALM1—type 2 diabetes mellitus	5.16e-05	0.00198	CbGpPWpGaD
Dofetilide—Dizziness—Orlistat—type 2 diabetes mellitus	5.16e-05	0.000961	CcSEcCtD
Dofetilide—Asthenia—Metformin—type 2 diabetes mellitus	5.16e-05	0.000961	CcSEcCtD
Dofetilide—CYP3A4—Farnesoid X Receptor  Pathway—PPARGC1A—type 2 diabetes mellitus	5.14e-05	0.00197	CbGpPWpGaD
Dofetilide—Nausea—Gliclazide—type 2 diabetes mellitus	5.1e-05	0.000951	CcSEcCtD
Dofetilide—Abdominal pain—Losartan—type 2 diabetes mellitus	5.05e-05	0.00094	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.99e-05	0.000929	CcSEcCtD
Dofetilide—CYP3A4—Estrogen metabolism—GSTM1—type 2 diabetes mellitus	4.98e-05	0.00191	CbGpPWpGaD
Dofetilide—Rash—Valsartan—type 2 diabetes mellitus	4.98e-05	0.000927	CcSEcCtD
Dofetilide—Dermatitis—Valsartan—type 2 diabetes mellitus	4.97e-05	0.000927	CcSEcCtD
Dofetilide—Insomnia—Ramipril—type 2 diabetes mellitus	4.95e-05	0.000923	CcSEcCtD
Dofetilide—Headache—Valsartan—type 2 diabetes mellitus	4.94e-05	0.000921	CcSEcCtD
Dofetilide—Diarrhoea—Metformin—type 2 diabetes mellitus	4.92e-05	0.000916	CcSEcCtD
Dofetilide—Rash—Orlistat—type 2 diabetes mellitus	4.92e-05	0.000916	CcSEcCtD
Dofetilide—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000916	CcSEcCtD
Dofetilide—Dermatitis—Orlistat—type 2 diabetes mellitus	4.91e-05	0.000916	CcSEcCtD
Dofetilide—Headache—Orlistat—type 2 diabetes mellitus	4.89e-05	0.000911	CcSEcCtD
Dofetilide—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.88e-05	0.000909	CcSEcCtD
Dofetilide—Asthenia—Irbesartan—type 2 diabetes mellitus	4.87e-05	0.000907	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—GJA1—type 2 diabetes mellitus	4.86e-05	0.00186	CbGpPWpGaD
Dofetilide—KCNK2—Neuronal System—PRKCB—type 2 diabetes mellitus	4.85e-05	0.00186	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—AR—type 2 diabetes mellitus	4.82e-05	0.00185	CbGpPWpGaD
Dofetilide—Dizziness—Metformin—type 2 diabetes mellitus	4.75e-05	0.000886	CcSEcCtD
Dofetilide—Nausea—Valsartan—type 2 diabetes mellitus	4.69e-05	0.000874	CcSEcCtD
Dofetilide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.64e-05	0.000865	CcSEcCtD
Dofetilide—Nausea—Orlistat—type 2 diabetes mellitus	4.63e-05	0.000863	CcSEcCtD
Dofetilide—Asthenia—Losartan—type 2 diabetes mellitus	4.58e-05	0.000854	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—GNB3—type 2 diabetes mellitus	4.55e-05	0.00174	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—PPARGC1A—type 2 diabetes mellitus	4.55e-05	0.00174	CbGpPWpGaD
Dofetilide—Rash—Metformin—type 2 diabetes mellitus	4.53e-05	0.000845	CcSEcCtD
Dofetilide—Dermatitis—Metformin—type 2 diabetes mellitus	4.53e-05	0.000844	CcSEcCtD
Dofetilide—Headache—Metformin—type 2 diabetes mellitus	4.5e-05	0.000839	CcSEcCtD
Dofetilide—Dizziness—Irbesartan—type 2 diabetes mellitus	4.49e-05	0.000836	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—AVP—type 2 diabetes mellitus	4.48e-05	0.00172	CbGpPWpGaD
Dofetilide—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.48e-05	0.000834	CcSEcCtD
Dofetilide—Diarrhoea—Losartan—type 2 diabetes mellitus	4.37e-05	0.000814	CcSEcCtD
Dofetilide—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.33e-05	0.000806	CcSEcCtD
Dofetilide—Rash—Irbesartan—type 2 diabetes mellitus	4.28e-05	0.000797	CcSEcCtD
Dofetilide—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.27e-05	0.000796	CcSEcCtD
Dofetilide—Nausea—Metformin—type 2 diabetes mellitus	4.27e-05	0.000796	CcSEcCtD
Dofetilide—Headache—Irbesartan—type 2 diabetes mellitus	4.25e-05	0.000792	CcSEcCtD
Dofetilide—Dizziness—Losartan—type 2 diabetes mellitus	4.22e-05	0.000787	CcSEcCtD
Dofetilide—Nausea—Irbesartan—type 2 diabetes mellitus	4.03e-05	0.000751	CcSEcCtD
Dofetilide—Rash—Losartan—type 2 diabetes mellitus	4.02e-05	0.00075	CcSEcCtD
Dofetilide—Dermatitis—Losartan—type 2 diabetes mellitus	4.02e-05	0.000749	CcSEcCtD
Dofetilide—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—type 2 diabetes mellitus	4.01e-05	0.00154	CbGpPWpGaD
Dofetilide—Headache—Losartan—type 2 diabetes mellitus	4e-05	0.000745	CcSEcCtD
Dofetilide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—type 2 diabetes mellitus	3.95e-05	0.00152	CbGpPWpGaD
Dofetilide—Asthenia—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000732	CcSEcCtD
Dofetilide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—type 2 diabetes mellitus	3.91e-05	0.0015	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—NR3C1—type 2 diabetes mellitus	3.9e-05	0.0015	CbGpPWpGaD
Dofetilide—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—type 2 diabetes mellitus	3.85e-05	0.00148	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—SNAP25—type 2 diabetes mellitus	3.82e-05	0.00147	CbGpPWpGaD
Dofetilide—Nausea—Losartan—type 2 diabetes mellitus	3.79e-05	0.000707	CcSEcCtD
Dofetilide—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.74e-05	0.000698	CcSEcCtD
Dofetilide—Dizziness—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000675	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—HIF1A—type 2 diabetes mellitus	3.55e-05	0.00136	CbGpPWpGaD
Dofetilide—Rash—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000643	CcSEcCtD
Dofetilide—Dermatitis—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000643	CcSEcCtD
Dofetilide—Headache—Ramipril—type 2 diabetes mellitus	3.43e-05	0.000639	CcSEcCtD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—PPARGC1A—type 2 diabetes mellitus	3.39e-05	0.0013	CbGpPWpGaD
Dofetilide—Nausea—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000606	CcSEcCtD
Dofetilide—CYP3A4—Tryptophan metabolism—CYP2E1—type 2 diabetes mellitus	3.1e-05	0.00119	CbGpPWpGaD
Dofetilide—CYP3A4—Tryptophan metabolism—CYP1A2—type 2 diabetes mellitus	3.07e-05	0.00118	CbGpPWpGaD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—type 2 diabetes mellitus	3.04e-05	0.00117	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—type 2 diabetes mellitus	3e-05	0.00115	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—GNB3—type 2 diabetes mellitus	2.85e-05	0.00109	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—MAT1A—type 2 diabetes mellitus	2.66e-05	0.00102	CbGpPWpGaD
Dofetilide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—type 2 diabetes mellitus	2.6e-05	0.000996	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—ADCY5—type 2 diabetes mellitus	2.54e-05	0.000976	CbGpPWpGaD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—type 2 diabetes mellitus	2.51e-05	0.000963	CbGpPWpGaD
Dofetilide—CYP3A4—Tryptophan metabolism—CAT—type 2 diabetes mellitus	2.49e-05	0.000955	CbGpPWpGaD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—type 2 diabetes mellitus	2.48e-05	0.000952	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—type 2 diabetes mellitus	2.48e-05	0.00095	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—type 2 diabetes mellitus	2.46e-05	0.000945	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—type 2 diabetes mellitus	2.45e-05	0.000939	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—CASP3—type 2 diabetes mellitus	2.21e-05	0.000846	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—CALM1—type 2 diabetes mellitus	2.19e-05	0.000839	CbGpPWpGaD
Dofetilide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—type 2 diabetes mellitus	2.15e-05	0.000823	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—NFKB1—type 2 diabetes mellitus	2.06e-05	0.000791	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—PRKCB—type 2 diabetes mellitus	2.05e-05	0.000788	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—type 2 diabetes mellitus	2.03e-05	0.00078	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—type 2 diabetes mellitus	2.01e-05	0.000772	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—VEGFA—type 2 diabetes mellitus	1.87e-05	0.000718	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—TNF—type 2 diabetes mellitus	1.6e-05	0.000615	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—MTR—type 2 diabetes mellitus	1.35e-05	0.000518	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP11A1—type 2 diabetes mellitus	1.31e-05	0.000502	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—IL6—type 2 diabetes mellitus	1.29e-05	0.000497	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	1.29e-05	0.000495	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP2E1—type 2 diabetes mellitus	1.08e-05	0.000414	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP1A2—type 2 diabetes mellitus	1.07e-05	0.00041	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	1.07e-05	0.000409	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP1A2—type 2 diabetes mellitus	1.05e-05	0.000404	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GSTM1—type 2 diabetes mellitus	8.19e-06	0.000314	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	8.08e-06	0.00031	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	6.25e-06	0.00024	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	5.46e-06	0.000209	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	5.46e-06	0.000209	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	5.18e-06	0.000199	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	5.18e-06	0.000199	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	4.94e-06	0.000189	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	4.56e-06	0.000175	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	4.56e-06	0.000175	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	4.4e-06	0.000169	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	4.4e-06	0.000169	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	4.4e-06	0.000169	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	4.4e-06	0.000169	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	4.4e-06	0.000169	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	4.26e-06	0.000163	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	4.03e-06	0.000154	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	4.03e-06	0.000154	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	3.92e-06	0.00015	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	3.74e-06	0.000144	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	3.74e-06	0.000144	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	3.74e-06	0.000144	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	3.59e-06	0.000138	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	3.59e-06	0.000138	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	3.45e-06	0.000132	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	3.45e-06	0.000132	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	3.39e-06	0.00013	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	3.34e-06	0.000128	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	3.34e-06	0.000128	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	3.34e-06	0.000128	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	3.14e-06	0.00012	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	2.94e-06	0.000113	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	2.84e-06	0.000109	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	2.84e-06	0.000109	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	2.84e-06	0.000109	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	2.84e-06	0.000109	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	2.72e-06	0.000104	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	2.53e-06	9.69e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.36e-06	9.05e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.31e-06	8.87e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.31e-06	8.87e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.27e-06	8.7e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.25e-06	8.64e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.25e-06	8.64e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.25e-06	8.64e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.24e-06	8.59e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.2e-06	8.43e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.17e-06	8.34e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.02e-06	7.75e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.02e-06	7.75e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.02e-06	7.75e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.98e-06	7.61e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.97e-06	7.54e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.92e-06	7.38e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.85e-06	7.09e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.83e-06	7.01e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.83e-06	7.01e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.75e-06	6.72e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.75e-06	6.72e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.51e-06	5.79e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.51e-06	5.79e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.5e-06	5.77e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.48e-06	5.69e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.44e-06	5.52e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.4e-06	5.37e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.37e-06	5.27e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.35e-06	5.16e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.34e-06	5.14e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.31e-06	5.01e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.29e-06	4.95e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.24e-06	4.75e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.21e-06	4.66e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.18e-06	4.51e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.16e-06	4.44e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.15e-06	4.42e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.14e-06	4.37e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1e-06	3.85e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	9.84e-07	3.78e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	9.03e-07	3.46e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	8.63e-07	3.31e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	8.63e-07	3.31e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	7.9e-07	3.03e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	3.97e-07	1.52e-05	CbGpPWpGaD
